Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor. Its product candidates also comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor IIb, which is in Phase I clinical trials to treat patients with gastric or gastroesophageal junction and bladder cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 as a monotherapy in various cancers. The company's FP-1039 is in Phase Ib clinical trials to treat patients with malignant pleural mesothelioma. Its preclinical product candidates include FPA150, a CD8 T cell checkpoint inhibitor antibody; FPA154, a tetravalent agonistic antibody that activates glucocorticoid-induced tumor necrosis factor receptor; and FPT155, a CD80-Fc fusion protein, which modulates signaling pathways. The company has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; collaboration agreement with Roche; and license agreements with bluebird bio, Inc., Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. Five Prime Therapeutics, Inc. was founded in 2001 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FPRX
Previous Symbol
CUSIPN/A
Phone415-365-5600
Debt
Debt-to-Equity RatioN/A
Current Ratio8.42
Quick Ratio8.42
Price-To-Earnings
Trailing P/E Ratio-1.79
Forward P/E Ratio-2.23
P/E GrowthN/A
Sales & Book Value
Annual Sales$39.51 million
Price / Sales8.65
Cash FlowN/A
Price / Cash FlowN/A
Book Value$7.80 per share
Price / Book1.24
Profitability
EPS (Most Recent Fiscal Year)($5.38)
Net Income$-150,220,000.00
Net Margins-221.67%
Return on Equity-41.52%
Return on Assets-33.92%
Miscellaneous
Employees216
Outstanding Shares35,470,000
Market Cap$341.89 million
OptionableOptionable
Five Prime Therapeutics (NASDAQ:FPRX) Frequently Asked Questions
What is Five Prime Therapeutics' stock symbol?
Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."
How were Five Prime Therapeutics' earnings last quarter?
Five Prime Therapeutics Inc (NASDAQ:FPRX) announced its quarterly earnings data on Tuesday, November, 6th. The biotechnology company reported ($1.37) EPS for the quarter, missing the Zacks' consensus estimate of ($1.15) by $0.22. The biotechnology company had revenue of $5.77 million for the quarter, compared to analysts' expectations of $7.45 million. Five Prime Therapeutics had a negative return on equity of 41.52% and a negative net margin of 221.67%. View Five Prime Therapeutics' Earnings History.
When is Five Prime Therapeutics' next earnings date?
What price target have analysts set for FPRX?
9 Wall Street analysts have issued twelve-month price objectives for Five Prime Therapeutics' stock. Their forecasts range from $19.00 to $60.00. On average, they anticipate Five Prime Therapeutics' share price to reach $30.75 in the next twelve months. This suggests a possible upside of 219.0% from the stock's current price. View Analyst Price Targets for Five Prime Therapeutics.
What is the consensus analysts' recommendation for Five Prime Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Five Prime Therapeutics in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Five Prime Therapeutics.
Has Five Prime Therapeutics been receiving favorable news coverage?
Press coverage about FPRX stock has been trending positive on Sunday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Five Prime Therapeutics earned a news impact score of 3.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an impact on the company's share price in the near term.
Who are some of Five Prime Therapeutics' key competitors?
Some companies that are related to Five Prime Therapeutics include Zai Lab (ZLAB), Tricida (TCDA), Aimmune Therapeutics (AIMT), Phibro Animal Health (PAHC), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Nabriva Therapeutics (NBRV), Esperion Therapeutics (ESPR), Portola Pharmaceuticals (PTLA), Spectrum Pharmaceuticals (SPPI), Myovant Sciences (MYOV), G1 Therapeutics (GTHX), Insmed (INSM), Clovis Oncology (CLVS) and Kiniksa Pharmaceuticals (KNSA).
Who are Five Prime Therapeutics' key executives?
Five Prime Therapeutics' management team includes the folowing people:
- Dr. Lewis T. Williams, Founder & Exec. Chairman (Age 69)
- Mr. Aron Marc Knickerbocker, Pres, CEO & Director (Age 49)
- Mr. Francis W. Sarena, Chief Strategy Officer & Sec. (Age 47)
- Dr. Helen Louise Collins, Sr. VP & Chief Medical Officer (Age 55)
- Dr. Peder K. Jensen, Advisor & Director (Age 63)
Who are Five Prime Therapeutics' major shareholders?
Five Prime Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (11.34%), BlackRock Inc. (8.18%), Vanguard Group Inc (6.35%), Vanguard Group Inc. (6.35%), Dimensional Fund Advisors LP (3.98%) and DekaBank Deutsche Girozentrale (0.80%). Company insiders that own Five Prime Therapeutics stock include Francis Willard Sarena, Lewis T Williams and William R Ringo. View Institutional Ownership Trends for Five Prime Therapeutics.
Which major investors are selling Five Prime Therapeutics stock?
FPRX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Hilltop Holdings Inc., Virtus ETF Advisers LLC, Credit Suisse AG, Wells Fargo & Company MN and Vident Investment Advisory LLC. View Insider Buying and Selling for Five Prime Therapeutics.
Which major investors are buying Five Prime Therapeutics stock?
FPRX stock was bought by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale, Dimensional Fund Advisors LP, Wexford Capital LP, Vanguard Group Inc, Vanguard Group Inc., Westpac Banking Corp, BlackRock Inc. and Trexquant Investment LP. View Insider Buying and Selling for Five Prime Therapeutics.
How do I buy shares of Five Prime Therapeutics?
Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Five Prime Therapeutics' stock price today?
One share of FPRX stock can currently be purchased for approximately $9.64.
How big of a company is Five Prime Therapeutics?
Five Prime Therapeutics has a market capitalization of $341.89 million and generates $39.51 million in revenue each year. The biotechnology company earns $-150,220,000.00 in net income (profit) each year or ($5.38) on an earnings per share basis. Five Prime Therapeutics employs 216 workers across the globe.
What is Five Prime Therapeutics' official website?
How can I contact Five Prime Therapeutics?
Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600.
MarketBeat Community Rating for Five Prime Therapeutics (NASDAQ FPRX)
MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote "Outperform" if you believe FPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
